CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Drivers of US health care spending for persons with seizures and/or epilepsies, 2010–2018
-
8 2022
-
-
Source: Epilepsia. 63(8):2144-2154
[PDF-498.13 KB]
Details:
-
Alternative Title:Epilepsia
-
Personal Author:
-
Description:Objective:
This study was undertaken to characterize spending for persons classified with seizure or epilepsy and to determine whether spending has increased over time.
Methods:
In this cross-sectional study, we pooled data from the Medical Expenditure Panel Survey (MEPS) household component files for 2010–2018. We matched cases to controls on age and sex of a population-based sample of MEPS respondents (community-dwelling persons of all ages) with records associated with a medical event (e.g., outpatient visit, hospital inpatient) for seizure, epilepsy, or both. Outcomes were weighted to be representative of the civilian, non-institutionalized population. We estimated the treated prevalence of epilepsy and seizure, health care spending overall and by site of care, and trends in spending growth.
Results:
We identified 1078 epilepsy cases and 2344 seizure cases. Treated prevalence was .38% (95% confidence interval [CI] = .34–.41) for epilepsy, .76% (95% CI = .71–.81) for seizure, and 1.14% (95% CI = 1.08–1.20) for epilepsy or seizure. The difference in annual spending for cases compared to controls was $4580 (95% CI = $3362–$5798) for epilepsy, $7935 (95% CI, $6237–$9634) for seizure, and $6853 (95% CI = $5623–$8084) for epilepsy or seizure, translating into aggregate costs of $5.4 billion, $19.0 billion, and $24.5 billion. From 2010 to 2018, the annual growth rate in total spending incurred for seizures and/or epilepsies was 7.6% compared to 3.6% among controls.
Significance:
US economic burden of seizures and/or epilepsies is substantial and warrants interventions focused on their unique and overlapping causes.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:35583854
-
Pubmed Central ID:PMC10969856
-
Document Type:
-
Funding:
-
Volume:63
-
Issue:8
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
